Fluoxetine: possible link to foetal cardiac defects

Infants exposed to fluoxetine during early gestation may have a slightly increased risk of congenital cardiac defects, the MHRA has advised. The increased risk, estimated to affect fewer than 2 in 100 pregnancies, is similar to that associated with paroxetine. Data are insufficient to draw conclusions about other SSRIs.

The possibility of cardiac defects in children exposed to fluoxetine in the womb should be weighed against the risks of untreated depression in pregnancy, which include low birth weight and preterm delivery. 

Further information: MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more